Full Text View
Tabular View
No Study Results Posted
Related Studies
Electrophysiologic Measures of Treatment Response in Alzheimer Disease
This study has been completed.
Study NCT00018278   Information provided by Department of Veterans Affairs
First Received: July 3, 2001   Last Updated: January 20, 2009   History of Changes

July 3, 2001
January 20, 2009
October 1998
 
 
 
Complete list of historical versions of study NCT00018278 on ClinicalTrials.gov Archive Site
 
 
 
Electrophysiologic Measures of Treatment Response in Alzheimer Disease
Verbal Memory ERPs as Indices of Treatment Response in Alzheimer Disease

The main purpose of this study is to determine the electrophysiological effects of cholinergic therapy (cholinesterase inhibitors and transdermal nicotine) in Alzheimer disease. The attempt will be to locate electrophysiological markers and predictors of cognitive and clinical treatment response.

 
Phase IV
Interventional
Treatment, Non-Randomized, Open Label, Uncontrolled, Crossover Assignment, Efficacy Study
Alzheimer Disease
  • Drug: Aricept
  • Drug: Exelon
  • Drug: Nicoderm Patch
 
 

*   Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
 
Completed
 
September 2001
 

Patients diagnosed with mild to moderate probable Alzheimer's disease (mini-mental state exam scores between 15-27), and normal controls (age generally between 60-85). Subjects must either be planning to start daily cholinesterase therapy (e.g. Aricept, Exelon) or willing to try a transdermal nicotine patch for two 8 hour periods.

Both
55 Years to 85 Years
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00018278
 
AGCG-004-98S
Department of Veterans Affairs
 
Investigator: Vincente Iragui, M.D., Ph.D
Investigator: Shuanna Morris, Ph.D.
Department of Veterans Affairs
December 2004

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP